clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2022-2-55-68clinvest-618Research ArticleБЕЗОПАСНОСТЬ ЛЕКАРСТВDRUG SAFETYЛекарственно-индуцированное внутримозговое кровоизлияниеDrug-induced intracerebral hemorrhagehttps://orcid.org/0000-0002-0401-1132ЛистратовА. И.ListratovA. I.

Листратов Александр Иванович - ординатор 2-го года кафедры терапии и полиморбидной патологии имени академика М.С. Вовси РМАНПО Минздрава России.

Москва.

SPIN-код: 1357-7122

Alexander I. Listratov - 2-year resident of the Department of Therapy and Polymorbid Pathology named after academician M.S. Vovsi RMACPE MOH Russia.

Moscow.

SPIN code: 1357-7122

alexanderlistratoff@yandex.ruhttps://orcid.org/0000-0003-1499-247XОстроумоваТ. М.OstroumovaT. M.

Остроумова Татьяна Максимовна – кандидат медицинских наук, ассистент кафедры нервных болезней и нейрохирургии ПМГМУ им. И.М. Сеченова Минздрава России (Сеченовский университет).

Москва.

SPIN-код: 5043-4713

Tatyana M. Ostroumova - Cand. Sci. Med., Assistant of the Department of Nervous Diseases and Neurosurgery of the I.M. Sechenov First MSMU MOH Russia (Sechenovskiy University).

Moscow.

SPIN code: 5043-4713

t.ostroumova3@gmail.comhttps://orcid.org/0000-0001-5801-3742КочетковА. И.KochetkovA. I.

Кочетков Алексей Иванович - кандидат медицинских наук, доцент кафедры терапии и полиморбидной патологии имени академика М.С. Вовси РМАНПО Минздрава России.

Москва.

SPIN-код: 9212-6010

Alexey I. Kochetkov - Cand. Sci. Med., Associate Professor of the Department of Department of Therapy and Polymorbid Pathology named after academician M.S. Vovsi RMACPE MOH Russia.

Moscow.

SPIN code: 9212-6010

ak_info@list.ruhttps://orcid.org/0000-0002-0795-8225ОстроумоваО. Д.OstroumovaO. D.

Остроумова Ольга Дмитриевна – доктор медицинских наук, профессор, зав. кафедрой терапии и полиморбидной патологии имени академика М.С. Вовси РМАНПО Минздрава России; профессор кафедры клинической фармакологии и пропедевтики внутренних болезней ПМГМУ им. И.М. Сеченова Минздрава России (Сеченовский университет).

Москва.

SPIN-код: 3910-6585

Olga D. Ostroumova - Dr. Sci. (Med.), professor, head of the Department of Therapy and Polymorbid Pathology named after academician M.S. Vovsi RMACPE MOH Russia; professor of the Department of Clinical Pharmacology and Propaedeutics of Internal Diseases I.M. Sechenov First MSMU MOH Russia (Sechenovskiy University).

Moscow.

SPIN code: 3910-6585

ostroumova.olga@mail.ruРоссийская медицинская академия непрерывного профессионального образования МЗ РФРоссияRussian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова Минздрава Российской Федерации (Сеченовский университет)РоссияI.M. Sechenov First MSMU MOH Russia (Sechenovskiy University)Russian FederationРоссийская медицинская академия непрерывного профессионального образования МЗ РФ; Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава Российской Федерации (Сеченовский университет)РоссияRussian Medical Academy of Continuous Professional Education» of the Ministry of Healthcare of the Russian Federation; I.M. Sechenov First MSMU MOH Russia (Sechenovskiy University)Russian Federation202202082022025568Copyright © Листратов А.И., Остроумова Т.М., Кочетков А.И., Остроумова О.Д., 20222022Листратов А.И., Остроумова Т.М., Кочетков А.И., Остроумова О.Д.Listratov A.I., Ostroumova T.M., Kochetkov A.I., Ostroumova O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/618

Внутримозговое кровоизлияние (ВМК), являющееся одной из форм геморрагического инсульта, представляет собой чрезвычайно серьёзное заболевание. Данная патология характеризуется крайне высокими уровнями инвалидизации и смертности. Несмотря на совершенствование терапии тех заболеваний, которые могут приводить к ВМК, его частота в настоящее время увеличивается, что в значительной степени обусловлено применением лекарственных средств (ЛС), в таком случае применяется термин «лекарственно-индуцированное внутримозговое кровоизлияние» (ЛИ ВМК). Одной из главных причин ЛИ ВМК является увеличение частоты назначения антикоагулянтной терапии для профилактики ишемического инсульта при фибрилляции предсердий, а также двойной антитромботической терапии. Кроме антикоагулянтов, к развитию данной патологии могут приводить тромболитические препараты. Согласно литературным данным, увеличение риска развития ВМК также ассоциировано с терапией антидепрессантами из группы селективных ингибиторов обратного захвата серотонина, а также статинов в высоких дозировках. Факторами риска данной нежелательной реакции являются возраст, курение, артериальная гипертензия и тромбоцитопения. Лечение ЛИ ВМК является чрезвычайно сложной задачей и включает отмену препарата-индуктора, антигипертензивную терапию, коррекции внутричерепной гипертензии, а также, в ряде случаев, введение антидотов. Основным методом профилактики является применение антитромбоцитарных препаратов и других ЛС, применение которых ассоциировано с повышенным риском развития ЛИ ВМК, в строгом соответствии с современными протоколами и рекомендациями.

Intracerebral hemorrhage (ICH), which is a form of hemorrhagic stroke, is an extremely serious disease. This pathology is characterized by very high levels of disability and mortality. Despite the improvement in the treatment of those diseases that can lead to ICH, its frequency is currently increasing, which is largely due to the use of drugs, in which case the term «drug-induced intracerebral hemorrhage» (DI ICH) is used. One of the main reasons for drug-induced ICH is an increase in the frequency of prescribing anticoagulant therapy for the prevention of ischemic stroke in atrial fibrillation, as well as dual antithrombotic therapy. In addition to anticoagulants, thrombolytic drugs can lead to the development of this pathology. According to the literature, an increase in the risk of developing ICH is also associated with therapy with antidepressants from the group of selective serotonin reuptake inhibitors, as well as high doses of statins. Risk factors for this adverse reaction are age, smoking, hypertension, and thrombocytopenia. Treatment of DI ICH is an extremely difficult task and includes the withdrawal of the culprit medication, antihypertensive therapy, correction of intracranial hypertension, and, in some cases, the administration of antidotes. The main method of prevention is the use of antiplatelet drugs and other drugs, the use of which is associated with an increased risk of developing DI ICH, in strict accordance with modern protocols and recommendations.

внутримозговое кровоизлияниелекарственно-индуцированное внутримозговое кровоизлияниеантикоагулянтыантиагрегантытромболитические препаратыстатиныселективные ингибиторы обратного захвата серотонинанежелательные лекарственные реакцииintracerebral hemorrhagedrug-induced intracerebral hemorrhageanticoagulantsantiplatelet agentsthrombolytic drugsstatinsselective serotonin reuptake inhibitorsunwanted drug reactionsReferencesКлинические рекомендации. Геморрагический инсульт. Минздрав России, Ассоциация нейрохирургов России, Всероссийское общество неврологов, Ассоциация анестезиологов и реаниматологов России, Ассоциация реабилитологов России. Пересмотр 2020 г. Доступно по: https://ruans.org/Text/Guidelines/hemorrhagic_stroke-2020.pdf. Ссылка активна на 18.06.2022.Klinicheskie rekomendacii. Gemorragicheskij insul’t. Minzdrav Rossii, Associaciya nejrohirurgov Rossii, Vserossijskoe obshchestvo nevrologov, Associaciya anesteziologov i reanimatologov Rossii, Associaciya reabilitologov Rossii. Peresmotr 2020 g. (In Russ). Доступно по: https://ruans.org/Text/Guidelines/hemorrhagic_stroke-2020.pdf. Ссылка активна на 18.06.2022.Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11(8):720–31. doi: 10.1016/S1474-4422(12)70104-7Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 2012;11(8):720–31. doi: 10.1016/S1474-4422(12)70104-7An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke. 2017;19(1):3–10. doi: 10.5853/jos.2016.00864An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke. 2017;19(1):3–10. doi: 10.5853/jos.2016.00864Unnithan AKA, Mehta P. Hemorrhagic Stroke. [Updated 2022 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK559173/. Accessed June 18, 2022.Unnithan AKA, Mehta P. Hemorrhagic Stroke. [Updated 2022 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK559173/. Accessed June 18, 2022.GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. doi: 10.1016/S1474-4422(21)00252-0GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. doi: 10.1016/S1474-4422(21)00252-0Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 рр.: 237–51.Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 рр.: 237–51.Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87–99. doi: 10.1161/STROKEAHA.106.476648Adams HP Jr, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39(1):87–99. doi: 10.1161/STROKEAHA.106.476648Cheng Z, Geng X, Gao J, et al. Intravenous Administration of Standard Dose Tirofiban after Mechanical Arterial Recanalization is Safe and Relatively Effective in Acute Ischemic Stroke. Aging Dis. 2019;10(5):1049–57. doi: 10.14336/AD.2018.0922Cheng Z, Geng X, Gao J, et al. Intravenous Administration of Standard Dose Tirofiban after Mechanical Arterial Recanalization is Safe and Relatively Effective in Acute Ischemic Stroke. Aging Dis. 2019;10(5):1049–57. doi: 10.14336/AD.2018.0922Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005;36(8):1801–7. doi: 10.1161/01.STR.0000174189.81153.85Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005;36(8):1801–7. doi: 10.1161/01.STR.0000174189.81153.85Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36(7):1588–93. doi: 10.1161/01.STR.0000170642.39876.f2Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36(7):1588–93. doi: 10.1161/01.STR.0000170642.39876.f2Namazi MH, Saemifard F, Pishgahi M. One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series. Arch Acad Emerg Med. 2020;8(1):e42. doi: 10.22037/aaem.v8i1.649Namazi MH, Saemifard F, Pishgahi M. One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series. Arch Acad Emerg Med. 2020;8(1):e42. doi: 10.22037/aaem.v8i1.649Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. doi: 10.1056/NEJMoa1107039Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. doi: 10.1056/NEJMoa1107039Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LYtrial. Stroke. 2012;43(6):1511–7. doi: 10.1161/STROKEAHA.112.650614Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LYtrial. Stroke. 2012;43(6):1511–7. doi: 10.1161/STROKEAHA.112.650614Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304–12. doi: 10.1161/STROKEAHA.113.004506Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45(5):1304–12. doi: 10.1161/STROKEAHA.113.004506Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. doi: 10.1056/NEJMoa1310907Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104. doi: 10.1056/NEJMoa1310907Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):287S-3I0S. doi: 10.1378/chest.126.3_suppl.287SLevine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):287S-3I0S. doi: 10.1378/chest.126.3_suppl.287SMantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017;129(25):3379–85. doi: 10.1182/blood-2017-02-767285Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood. 2017;129(25):3379–85. doi: 10.1182/blood-2017-02-767285Ungprasert P, Matteson EL, Thongprayoon C. Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. Stroke. 2016;47(2):356–64. doi: 10.1161/STROKEAHA.115.011678Ungprasert P, Matteson EL, Thongprayoon C. Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. Stroke. 2016;47(2):356–64. doi: 10.1161/STROKEAHA.115.011678Amarenco P, Bogousslavsky J, Callahan A III et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59. doi: 10.1056/NEJMoa061894Amarenco P, Bogousslavsky J, Callahan A III et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59. doi: 10.1056/NEJMoa061894Kuramatsu JB, Huttner HB. Management of oral anticoagulation after intracerebral hemorrhage. Int J Stroke. 2019;14(3):238–46. doi: 10.1177/1747493019828555Kuramatsu JB, Huttner HB. Management of oral anticoagulation after intracerebral hemorrhage. Int J Stroke. 2019;14(3):238–46. doi: 10.1177/1747493019828555Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol. 2016 Aug 11;8:93–107. doi: 10.2147/CPAA.S105165Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol. 2016 Aug 11;8:93–107. doi: 10.2147/CPAA.S105165Morotti A, Goldstein JN. Anticoagulant-associated intracerebral hemorrhage. Brain Hemorrhages. 2020;1(1):89–94. doi: 10.1016/j.hest.2020.01.001Morotti A, Goldstein JN. Anticoagulant-associated intracerebral hemorrhage. Brain Hemorrhages. 2020;1(1):89–94. doi: 10.1016/j.hest.2020.01.001Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990; 21(5):726–30. doi: 10.1161/01.str.21.5.726Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990; 21(5):726–30. doi: 10.1161/01.str.21.5.726Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9. doi: 10.1016/j.ahj.2005.04.017Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151(3):713–9. doi: 10.1016/j.ahj.2005.04.017Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700– 5. doi: 10.1016/j.amjmed.2006.07.034Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700– 5. doi: 10.1016/j.amjmed.2006.07.034Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43(7):1812–7. doi: 10.1161/STROKEAHA.112.652065Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43(7):1812–7. doi: 10.1161/STROKEAHA.112.652065Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8. doi: 10.1182/blood-2014-07-590323Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014;124(15):2450–8. doi: 10.1182/blood-2014-07-590323Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi: 10.1016/S0140-6736(13)62343-0Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi: 10.1016/S0140-6736(13)62343-0Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63(20):2141–7. doi: 10.1016/j.jacc.2014.02.549Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63(20):2141–7. doi: 10.1016/j.jacc.2014.02.549Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35(28):1873–80. doi: 10.1093/eurheartj/ehu083Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35(28):1873–80. doi: 10.1093/eurheartj/ehu083Gulati S, Solheim O, Carlsen SM, et al. Risk of intracranial hemorrhage (RICH) in users oforal antithrombotic drugs: Nationwide pharmacoepidemiological study. PLoS One. 2018;13(8):e0202575. doi: 10.1371/journal.pone.0202575Gulati S, Solheim O, Carlsen SM, et al. Risk of intracranial hemorrhage (RICH) in users oforal antithrombotic drugs: Nationwide pharmacoepidemiological study. PLoS One. 2018;13(8):e0202575. doi: 10.1371/journal.pone.0202575Maïer B, Desilles JP, Mazighi M. Intracranial Hemorrhage After Reperfusion Therapies in Acute Ischemic Stroke Patients. Front Neurol. 2020;11:599908. doi: 10.3389/fneur.2020.599908Maïer B, Desilles JP, Mazighi M. Intracranial Hemorrhage After Reperfusion Therapies in Acute Ischemic Stroke Patients. Front Neurol. 2020;11:599908. doi: 10.3389/fneur.2020.599908Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38(8):2279–83. doi: 10.1161/STROKEAHA.107.487009Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38(8):2279–83. doi: 10.1161/STROKEAHA.107.487009Qureshi AI, Hussain MS, Nasar A, et al. Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States. Cardiovasc Drugs Ther. 2005;19(5):371–3. doi: 10.1007/s10557-005-4390-3Qureshi AI, Hussain MS, Nasar A, et al. Intracranial hemorrhages associated with intravenous platelet glycoprotein IIB/IIIA receptor inhibitors in the United States. Cardiovasc Drugs Ther. 2005;19(5):371–3. doi: 10.1007/s10557-005-4390-3Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060– 5. doi: 10.1161/01.STR.0000080678.09344.8DAriesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060– 5. doi: 10.1161/01.STR.0000080678.09344.8DNational Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43(8):2149–56. doi: 10.1161/STROKEAHA.112.655894McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43(8):2149–56. doi: 10.1161/STROKEAHA.112.655894Tapia-Pérez JH, Rupa R, Zilke R, Gehring S, Voellger B, Schneider T. Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. Neurosurg Rev. 2013;36(2):279–87. doi: 10.1007/s10143-012-0431-0Tapia-Pérez JH, Rupa R, Zilke R, Gehring S, Voellger B, Schneider T. Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage. Neurosurg Rev. 2013;36(2):279–87. doi: 10.1007/s10143-012-0431-0Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79(18):1862–5. doi: 10.1212/WNL.0b013e318271f848Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology. 2012;79(18):1862–5. doi: 10.1212/WNL.0b013e318271f848Aarts N, Akoudad S, Noordam R, et al. Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. Stroke. 2014;45(7):1951–7. doi: 10.1161/STROKEAHA.114.004990Aarts N, Akoudad S, Noordam R, et al. Inhibition of serotonin reuptake by antidepressants and cerebral microbleeds in the general population. Stroke. 2014;45(7):1951–7. doi: 10.1161/STROKEAHA.114.004990Liu L, Fuller M, Behymer TP, et al. Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome. Stroke. 2020;51(4):1135–41. doi: 10.1161/STROKEAHA.119.028406Liu L, Fuller M, Behymer TP, et al. Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome. Stroke. 2020;51(4):1135–41. doi: 10.1161/STROKEAHA.119.028406Kubiszewski P, Sugita L, Kourkoulis C, et al. Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity [published online ahead of print, 2020 Aug 31]. JAMA Neurol. 2020;78(1):1–8. doi: 10.1001/jamaneurol.2020.3142Kubiszewski P, Sugita L, Kourkoulis C, et al. Association of Selective Serotonin Reuptake Inhibitor Use After Intracerebral Hemorrhage With Hemorrhage Recurrence and Depression Severity [published online ahead of print, 2020 Aug 31]. JAMA Neurol. 2020;78(1):1–8. doi: 10.1001/jamaneurol.2020.3142Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation. 2002;105(8):1004–11. doi: 10.1161/hc0802.104331Weitz JI, Buller HR. Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation. 2002;105(8):1004–11. doi: 10.1161/hc0802.104331Islam MM, Poly TN, Walther BA, et al. Risk of Hemorrhagic Stroke in Patients Exposed to Nonsteroidal Anti-Inflammatory Drugs: A Meta-Analysis of Observational Studies. Neuroepidemiology. 2018;51(3-4):166–76. doi: 10.1159/000490741Islam MM, Poly TN, Walther BA, et al. Risk of Hemorrhagic Stroke in Patients Exposed to Nonsteroidal Anti-Inflammatory Drugs: A Meta-Analysis of Observational Studies. Neuroepidemiology. 2018;51(3-4):166–76. doi: 10.1159/000490741Hou PC, Lin FJ, Lin SY, et al. Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Anti-inflammatory Drugs: A Nested Case-Control Study. Ann Pharmacother. 2021;55(8):941–8. doi: 10.1177/1060028020980417Hou PC, Lin FJ, Lin SY, et al. Risk of Intracranial Hemorrhage With Concomitant Use of Antidepressants and Nonsteroidal Anti-inflammatory Drugs: A Nested Case-Control Study. Ann Pharmacother. 2021;55(8):941–8. doi: 10.1177/1060028020980417Jeong HE, Oh IS, Kim WJ, Shin JY. Risk of Major Adverse Cardiovascular Events Associated with Concomitant Use of Antidepressants and Non-steroidal Anti-inflammatory Drugs: A Retrospective Cohort Study. CNS Drugs. 2020;34(10):1063–74. doi: 10.1007/s40263-020-00750-4Jeong HE, Oh IS, Kim WJ, Shin JY. Risk of Major Adverse Cardiovascular Events Associated with Concomitant Use of Antidepressants and Non-steroidal Anti-inflammatory Drugs: A Retrospective Cohort Study. CNS Drugs. 2020;34(10):1063–74. doi: 10.1007/s40263-020-00750-4Choi NK, Park BJ, Jeong SW, Yu KH, Yoon BW. Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. Stroke. 2008;39(3):845–9. doi: 10.1161/STROKEAHA.107.497040Choi NK, Park BJ, Jeong SW, Yu KH, Yoon BW. Nonaspirin nonsteroidal anti-inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study. Stroke. 2008;39(3):845–9. doi: 10.1161/STROKEAHA.107.497040Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450–60. doi: 10.1056/NEJM200105103441907Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001;344(19):1450–60. doi: 10.1056/NEJM200105103441907Qureshi AI, Suri MF, Ostrow PT, et al. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery. 2003;52(5):1041–7; discussion 1047-8.Qureshi AI, Suri MF, Ostrow PT, et al. Apoptosis as a form of cell death in intracerebral hemorrhage. Neurosurgery. 2003;52(5):1041–7; discussion 1047-8.Slemmer JE, Shacka JJ, Sweeney MI, Weber JT. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem. 2008;15(4):404–14. doi: 10.2174/092986708783497337Slemmer JE, Shacka JJ, Sweeney MI, Weber JT. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem. 2008;15(4):404–14. doi: 10.2174/092986708783497337Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53–63. doi: 10.1016/S1474-4422(05)70283-0Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006;5(1):53–63. doi: 10.1016/S1474-4422(05)70283-0Chen S, Zeng L, Hu Z. Progressing haemorrhagic stroke: categories, causes, mechanisms and managements. J Neurol. 2014;261(11):2061–78. doi: 10.1007/s00415-014-7291-1Chen S, Zeng L, Hu Z. Progressing haemorrhagic stroke: categories, causes, mechanisms and managements. J Neurol. 2014;261(11):2061–78. doi: 10.1007/s00415-014-7291-1Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64. doi: 10.1212/01.wnl.0000138428.40673.83Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63(6):1059–64. doi: 10.1212/01.wnl.0000138428.40673.83James RF, Palys V, Lomboy JR, Lamm JR Jr, Simon SD. The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage. Neurosurg Focus. 2013;34(5):E6. doi: 10.3171/2013.2.FOCUS1328James RF, Palys V, Lomboy JR, Lamm JR Jr, Simon SD. The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage. Neurosurg Focus. 2013;34(5):E6. doi: 10.3171/2013.2.FOCUS1328Skop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37(1):12–6. doi: 10.1016/S0033-3182(96)71592-XSkop BP, Brown TM. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics. 1996;37(1):12–6. doi: 10.1016/S0033-3182(96)71592-XOoneda G, Yoshida Y, Suzuki K, et al. Smooth muscle cells in the development of plasmatic arterionecrosis, arteriosclerosis, and arterial contraction. Blood Vessels. 1978;15(1-3):148–56. doi: 10.1159/000158160Ooneda G, Yoshida Y, Suzuki K, et al. Smooth muscle cells in the development of plasmatic arterionecrosis, arteriosclerosis, and arterial contraction. Blood Vessels. 1978;15(1-3):148–56. doi: 10.1159/000158160Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147. doi: 10.1016/j.bcp.2020.114147Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020;180:114147. doi: 10.1016/j.bcp.2020.114147Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10:25–32. doi: 10.2147/VHRM.S54159Park K, Bavry AA. Risk of stroke associated with nonsteroidal anti-inflammatory drugs. Vasc Health Risk Manag. 2014;10:25–32. doi: 10.2147/VHRM.S54159Лекарственнo-индуцированные заболевания. Том II: Монография / под общ. ред. Д. А. Сычёва, О. Д. Остроумовой. — М.: Прометей, 2022. — 536 с.Lekarstvenno-inducirovannye zabolevaniya. Tom II: Monografiya / Ed by DA Sychev, OD Ostroumova. Moscow: Prometej, 2022. (In Russ).Leasure AC, King ZA, Torres-Lopez V, et al. Racial/ethnic disparities in the risk of intracerebral hemorrhage recurrence. Neurology. 2020;94(3):e314–e322. doi: 10.1212/WNL.0000000000008737Leasure AC, King ZA, Torres-Lopez V, et al. Racial/ethnic disparities in the risk of intracerebral hemorrhage recurrence. Neurology. 2020;94(3):e314–e322. doi: 10.1212/WNL.0000000000008737O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–75. doi: 10.1016/S0140-6736(16)30506-2O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761–75. doi: 10.1016/S0140-6736(16)30506-2Skidmore CT, Andrefsky J. Spontaneous intracerebral hemorrhage: epidemiology, pathophysiology, and medical management. Neurosurg Clin N Am. 2002;13(3):281-v. doi: 10.1016/s1042-3680(02)00019-0Skidmore CT, Andrefsky J. Spontaneous intracerebral hemorrhage: epidemiology, pathophysiology, and medical management. Neurosurg Clin N Am. 2002;13(3):281-v. doi: 10.1016/s1042-3680(02)00019-0Iakovou I, Dangas G, Mintz GS, et al. Comparison of frequency of hemorrhagic stroke in patients >75 years versus< or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Am J Cardiol. 2004;93(3):346–9. doi: 10.1016/j.amjcard.2003.10.018Iakovou I, Dangas G, Mintz GS, et al. Comparison of frequency of hemorrhagic stroke in patients >75 years versus< or =75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Am J Cardiol. 2004;93(3):346–9. doi: 10.1016/j.amjcard.2003.10.018Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43(3):531–7. doi: 10.1053/j.ajkd.2003.11.012Farooq V, Hegarty J, Chandrasekar T, et al. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis. 2004;43(3):531–7. doi: 10.1053/j.ajkd.2003.11.012Huynh T, Cox JL, Massel D, et al. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J. 2004;148(1):86–91. doi: 10.1016/j.ahj.2004.02.006Huynh T, Cox JL, Massel D, et al. Predictors of intracranial hemorrhage with fibrinolytic therapy in unselected community patients: a report from the FASTRAK II project. Am Heart J. 2004;148(1):86–91. doi: 10.1016/j.ahj.2004.02.006National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7. doi: 10.1056/NEJM199512143332401National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7. doi: 10.1056/NEJM199512143332401Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925–33. doi: 10.1016/S1474-4422(16)30076-XWhiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925–33. doi: 10.1016/S1474-4422(16)30076-XMehta RH, Cox M, Smith EE, et al. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45(8):2263–9. doi: 10.1161/STROKEAHA.114.005019Mehta RH, Cox M, Smith EE, et al. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45(8):2263–9. doi: 10.1161/STROKEAHA.114.005019Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–41. doi: 10.1161/01.str.32.2.438Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2):438–41. doi: 10.1161/01.str.32.2.438Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score [published correction appears in Stroke. 2012 Sep;43(9):e102]. Stroke. 2012;43(6):1524–31. doi: 10.1161/STROKEAHA.111.644815Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score [published correction appears in Stroke. 2012 Sep;43(9):e102]. Stroke. 2012;43(6):1524–31. doi: 10.1161/STROKEAHA.111.644815Nisar T, Hanumanthu R, Khandelwal P. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models. J Stroke Cerebrovasc Dis. 2019;28(11):104360. doi: 10.1016/j.jstrokecerebrovasdis.2019.104360Nisar T, Hanumanthu R, Khandelwal P. Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models. J Stroke Cerebrovasc Dis. 2019;28(11):104360. doi: 10.1016/j.jstrokecerebrovasdis.2019.104360Maestrini I, Strbian D, Gautier S, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology. 2015;85(16):1408–16. doi: 10.1212/WNL.0000000000002029Maestrini I, Strbian D, Gautier S, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology. 2015;85(16):1408–16. doi: 10.1212/WNL.0000000000002029Maestrini I, Strbian D, Gautier S, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology. 2015;85(16):1408–16. doi: 10.1212/WNL.0000000000002029Maestrini I, Strbian D, Gautier S, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology. 2015;85(16):1408–16. doi: 10.1212/WNL.0000000000002029Gensicke H, Al Sultan AS, Strbian D, et al. Intravenous thrombolysis and platelet count [published correction appears in Neurology. 2018 Oct 30;91(18):852]. Neurology. 2018;90(8):e690–e697. doi: 10.1212/WNL.0000000000004982Gensicke H, Al Sultan AS, Strbian D, et al. Intravenous thrombolysis and platelet count [published correction appears in Neurology. 2018 Oct 30;91(18):852]. Neurology. 2018;90(8):e690–e697. doi: 10.1212/WNL.0000000000004982Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599–607. doi: 10.1093/qjmed/hcm076Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599–607. doi: 10.1093/qjmed/hcm076Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology. 2001;57(11):1993–9. doi: 10.1212/wnl.57.11.1993Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology. 2001;57(11):1993–9. doi: 10.1212/wnl.57.11.1993Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. doi: 10.1378/chest.10-0134Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. doi: 10.1378/chest.10-0134Ramasubbu R. SSRI treatment-associated stroke: causality assessment in two cases. Ann Pharmacother. 2004;38(7-8):1197–201. doi: 10.1345/aph.1D624Ramasubbu R. SSRI treatment-associated stroke: causality assessment in two cases. Ann Pharmacother. 2004;38(7-8):1197–201. doi: 10.1345/aph.1D624Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80–97. doi: 10.1080/07853890.2021.2017474Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80–97. doi: 10.1080/07853890.2021.2017474Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33(6):1465–73. doi: 10.1161/01.str.0000018589.56991.baBak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33(6):1465–73. doi: 10.1161/01.str.0000018589.56991.baWilson D, Charidimou A, Shakeshaft C, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology. 2016;86(4):360–6. doi: 10.1212/WNL.0000000000002310Wilson D, Charidimou A, Shakeshaft C, et al. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology. 2016;86(4):360–6. doi: 10.1212/WNL.0000000000002310Adachi T, Hoshino H, Takagi M, Fujioka S; Saiseikai Stroke Research Group. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin. Cerebrovasc Dis Extra. 2017;7(1):62–71. doi: 10.1159/000462985Adachi T, Hoshino H, Takagi M, Fujioka S; Saiseikai Stroke Research Group. Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin. Cerebrovasc Dis Extra. 2017;7(1):62–71. doi: 10.1159/000462985Macellari F, Paciaroni M, Agnelli G, Caso V. Neuroimaging in intracerebral hemorrhage. Stroke. 2014;45(3):903–8. doi: 10.1161/STROKEAHA.113.003701Macellari F, Paciaroni M, Agnelli G, Caso V. Neuroimaging in intracerebral hemorrhage. Stroke. 2014;45(3):903–8. doi: 10.1161/STROKEAHA.113.003701Romero J, Rosand J. Hemorrhagic cerebrovascular disease. Handb Clin Neurol. 2016:351–64. doi: 10.1016/b978-0-444-53485-9.00018-0Romero J, Rosand J. Hemorrhagic cerebrovascular disease. Handb Clin Neurol. 2016:351–64. doi: 10.1016/b978-0-444-53485-9.00018-0Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association. Stroke. 2015;46(7):2032–60. doi: 10.1161/STR.0000000000000069Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association / American Stroke Association. Stroke. 2015;46(7):2032–60. doi: 10.1161/STR.0000000000000069Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239– 45. doi: 10.1038/clpt.1981.154Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239– 45. doi: 10.1038/clpt.1981.154Сычёв Д. А., Остроумова О. Д., Переверзев А. П. и др. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020;6:113–26. doi: 10.18565/pharmateca.2020.6.113-126Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateca. 2020;6:113–26. (In Russ). doi: 10.18565/pharmateca.2020.6.113-126Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi: 10.15829/1560-4071-2020-3-3786Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ). doi: 10.15829/1560-4071-2020-3-3786Аракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi: 10.15829/1560-4071-2021-4594Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ). doi: 10.15829/1560-4071-2021-4594rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Аспирин® Кардио [доступ от 18.06.2022]. Доступ по ссылке: https://www.rlsnet.ru/drugs/aspirin-kardio-7424.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Аспирин® Кардио [доступ от 18.06.2022]. Доступ по ссылке: https://www.rlsnet.ru/drugs/aspirin-kardio-7424.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Брилинта® [доступ от 18.06.2022]. Доступ по ссылке: https://www.rlsnet.ru/drugs/brilinta-42456.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Брилинта® [доступ от 18.06.2022]. Доступ по ссылке: https://www.rlsnet.ru/drugs/brilinta-42456.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Эффиент® [доступ от 18.06.2022]. Доступ по ссылке: www.rlsnet.ru/drugs/effient-41998.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Эффиент® [доступ от 18.06.2022]. Доступ по ссылке: www.rlsnet.ru/drugs/effient-41998.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Плавикс® [доступ от 18.06.2022]. Доступ по ссылке: https://www.rlsnet.ru/drugs/plaviks-8690.rlsnet.ru/drugs [интернет]. РЛС. Реестр лекарственных средств России. Плавикс® [доступ от 18.06.2022]. Доступ по ссылке: https://www.rlsnet.ru/drugs/plaviks-8690.Российское кардиологическое общество (РКО). Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4076. doi:10.15829/29/1560-4071-2020-4076Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ). doi:10.15829/29/1560-4071-2020-4076Барбараш О. Л., Дупляков Д. В., Затейщиков Д. А. и др. Острый коронарный синдром без подъёма сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449. doi: 10.15829/1560-4071-2021-4449Barbarash OL, Duplyakov DV, Zateishchikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. (In Russ). doi: 10.15829/1560-4071-2021-4449Российское кардиологическое общество (РКО). Острый инфаркт миокарда с подъёмом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4103. doi: 10.15829/29/1560-4071-2020-4103Russian Society of Cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ). doi: 10.15829/29/1560-4071-2020-4103Шамалов Н. А., Хасанова Д. Р., Стаховская Л. В. и др. Реперфузионная терапия ишемического инсульта. Клинический протокол. — М., 2019. — 80 с.Shamalov NA, Hasanova DR, Stahovskaya LV, et al. Reperfuzionnaya terapiya ishemicheskogo insul’ta. Klinicheskij protokol. Moscow: 2019. (In Russ).

The authors declare that there are no conflicts of interest present.